Metrics to open potent and cytotoxic drug development facility
US-based contract manufacturer Metrics Inc is building a potent and cytotoxic drug development facility at its site in Greenville, North Carolina due to open early in 2009.
Part of a recent $18m (£12m) expansion, the new dedicated facility will provide total engineered containment of pharmaceutical processes through customised hard-wall isolation technologies. Because of these technologies, Metrics’ has eliminated any need for the use of powered air purifying respirators (PAPRs) in its new potent facility.
Equipment and change parts are dedicated exclusively to potent and cytotoxic use, and containment is achieved at levels approximately 30 nanograms per cubic meter of room air.
‘According to our internal research, Metrics’ new facility has raised the industry bar in providing potent handling capabilities for clients,’ said Phil Hodges, president.
The company provides quality pharmaceutical formulation development, clinical trial material (Phase I, II and III) and commercial manufacturing, and analytical development/validation services to the pharmaceutical industry.
It recently opened a 47,000ft2 facility addition housing four new analytical laboratories